Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (181-190 of 242) with videos related to

Pageof 25
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyMichael Benatar, Joanne Wuu, Peter M Andersen, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyMichael Benatar, Joanne Wuu, Peter M Andersen, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Neurobiology of Aging|October 31, 2012
Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in CaucasiansMartin A Kohli, Krista John-Williams, Ruchita Rajbhandary, et al.
Muscle & Nerve|June 29, 2026
At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform TrialEric A Macklin, James D Berry, Brittney A Harkey, et al.
The Lancet. Neurology|February 19, 2013
Controversies and priorities in amyotrophic lateral sclerosisMartin R Turner, Orla Hardiman, Michael Benatar, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 15, 2022
ALSUntangled #67: rituximabXiaoyan Li, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 5, 2025
ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)Javier Mascias Cadavid, Anna Mena Bravo, Paul Barkhaus, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Genome Research|August 24, 2019
Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variantsMichael N Edmonson, Aman N Patel, Dale J Hedges, et al.
Pageof 25

Showing results (181-190 of 242) with videos related to

Sort By:
Pageof 25
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyMichael Benatar, Joanne Wuu, Peter M Andersen, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyMichael Benatar, Joanne Wuu, Peter M Andersen, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Neurobiology of Aging|October 31, 2012
Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in CaucasiansMartin A Kohli, Krista John-Williams, Ruchita Rajbhandary, et al.
Muscle & Nerve|June 29, 2026
At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform TrialEric A Macklin, James D Berry, Brittney A Harkey, et al.
The Lancet. Neurology|February 19, 2013
Controversies and priorities in amyotrophic lateral sclerosisMartin R Turner, Orla Hardiman, Michael Benatar, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 15, 2022
ALSUntangled #67: rituximabXiaoyan Li, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 5, 2025
ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)Javier Mascias Cadavid, Anna Mena Bravo, Paul Barkhaus, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Genome Research|August 24, 2019
Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variantsMichael N Edmonson, Aman N Patel, Dale J Hedges, et al.
Pageof 25